abstract |
The present invention is for treating cancer comprising a BRAF inhibitor (eg, vemurafenib) and / or a MEK inhibitor (eg, trametinib, RO5068760) in combination with an anti-tubulin compound of the invention or other known tubulin inhibitor. And the use of such compositions to treat cancers such as melanoma, drug resistant cancer and cancer metastasis. In one embodiment, the invention relates to a pharmaceutical composition comprising a tubulin inhibitor in combination with at least one of a BRAF inhibitor or MEK inhibitor and a pharmaceutically acceptable carrier. |